Social anxiety disorder

Medical Clinics of North America

Volumn 85, Issue 3, 2001, Pages 711-733

  Raj, B Ashok ^b   Sheehan, David V ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ATENOLOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BROMAZEPAM; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PLACEBO; PROPRANOLOL; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY NEUROSIS; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MECHANISM; GENETIC PREDISPOSITION; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; RATING SCALE; RELAXATION TRAINING; REVIEW; SOCIAL ADAPTATION; SOCIAL PHOBIA; TREATMENT OUTCOME;

EID: 0035039516     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70337-0     Document Type: Article

References (146)

1. Paroxetine in social anxiety disorder: A randomized placebo-controlled study
2. Comorbidity of anxiety, phobia, compulsion and depression
3. Role of exposure homework in phobia reduction: A controlled study
4. The relationship between DSM III symptom disorders (Axis I) and personality disorders (Axis II) in an outpatient population
5. Effects of four treatment methods on social phobic patients not suitable for insight-oriented psychotherapy
6. Social phobia: A comparative clinical study
7. A large open multicenter trial of clomipramine in the management of phobic disorders
8. Social phobia and overanxious disorder in school age children
9. Social phobia, MVP, and response to imipramine
10. Fluoxetine for the treatment of social phobia
11. Lifetime prevalence of psychiatric disorders in Edmonton
12. Effects of psychotherapy on comorbid conditions in generalized anxiety disorder
13. Phobia: Prevalence and risk factors
14. Comorbidity of Axis I psychiatric disorders in bulimia nervosa
15. The sleep architecture of social phobia
16. Eating disorders and antecedent anxiety disorders: A controlled study
17. Exposure and anxiety management in the treatment of social phobia
18. 2 challenge test in patients with social phobia
19. The prevalence of specific psychiatric disorders in Puerto Rico
20. Anxiety disorders and alcoholism: A study with inpatient alcoholics
21. The assessment and treatment of performance anxiety in musicians
22. A cognitive model of social phobia
23. The epidemiology of social phobia: Findings from the Duke epidemiological catchment area study
24. Treatment of social phobia with clonazepam and placebo
25. The Zurich study: XX. Social phobia and agoraphobia
26. Psychopharmacological treatment of avoidant personality disorder
27. A comparative outcome study of four cognitive therapies in the treatment of social anxiety
28. Secondary social phobia in patients with major depression
29. Panic and phobia
30. Adherence during sessions and homework in cognitive-behavioral group treatment of social phobia
31. Treatment of social phobia with bupropion
32. Cognitive modification versus pro-longed exposure in vivo: A comparison with agoraphobics as subjects
33. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine: A double-blind placebo-controlled study
34. The treatment of social phobia: Real-life rehearsal with nonprofessional therapists
35. Treatment of social phobia by homework exposure
36. Avoidant disorder and social phobia in children and adolescents
37. DSM-IIIR disorders in New Zealand 18 year olds
38. Cognitive-behavioral versus exposure treatment for social phobia: A meta-analysis
39. A direct interview family study of social phobia
40. Cognitive-behavioral and pharmacological treatments of social phobia
41. Comorbidity of anxiety disorders in a multicenter anxiety study
42. The infrequency of "pure culture" diagnosis among the anxiety disorders
43. Treatment of social phobia with clonidine
44. Treatment of social phobia with atenolol
45. High dose carbon dioxide challenge test in anxiety disorder patients
46. Cognitive-behavioral and pharmacological treatment for social phobia: A meta-analysis
47. Comorbidity of psychiatric diagnosis in anorexia nervosa
48. Cognitive and behavioral treatments for social phobia: A critical analysis
49. Cognitive-behavioral group treatment of social phobia: Comparison to a credible placebo control
50. Psychometric properties of the Liebowitz Social Anxiety Scale
51. DSM-IIIR subtypes of social phobia: Comparison of generalized social phobics and public speaking phobics
52. Avoidant personality disorder and the generalized subtype of social phobia
53. Dismantling cognitive-behavioral group therapy for social phobia
54. Heritability of personality traits in adult male twins
55. Prevalence of psychiatric disorders in Taiwan defined by the Chinese diagnostic interview schedule
56. Abnormal peripheral benzodiazepine receptor density associated with generalized social phobia
57. Biological basis of childhood shyness
58. Moclobemide in social phobia: A double-blind, placebo-controlled clinical study
59. Sertraline for social phobia: A double-blind, placebo-controlled crossover study
60. The genetic epidemiology of phobias in women: The interrelationship of agoraphobia, social phobia, situational phobia and simple phobia
61. Lifetime and 12 month prevalence of DSM III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
62. Social phobia subtypes in the national comorbidity survey
63. The relation between alcohol problems and the anxiety disorders
64. Psychiatric epidemiology in Korea: Part I: Gender and age differences in Seoul
65. Comorbidity and social phobia: Clinical and epidemiological issues
66. Homework compliance, perceptions of control and out-come of cognitive-behavioral treatment of social phobia
67. Responses of generalized and discrete social phobics during public speaking
68. Social phobia
69. MAOIs: Impact on social behavior
70. Social phobia: Review of a neglected anxiety disorder
71. Phenelzine versus atenolol in social phobia: A placebo controlled comparison
72. Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study
73. Cognitive factors in social anxiety and its treatment
74. Alprazolam in the treatment of social phobia
75. Agoraphobia, simple phobia and social phobia in the National Comorbidity Survey
76. Different ages of onset in varieties of phobia
77. A controlled evaluation of systematic desensitization and social skills training for socially inadequate psychiatric patients
78. Exposure and cognitive restructuring for social phobia: A controlled study
79. A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls
80. Social phobia: Anxiety disorder comorbidity
81. Alcohol dependence and phobias: Clinical descriptions and relevance
82. Clonazepam in the treatment of social phobia: A pilot study
83. A pilot study of buspirone in the treatment of social phobia
84. Does behavioral treatment of social phobia lead to cognitive changes?
85. Moclobemide in social phobia: A controlled dose-response trial
86. Avoidant personality traits distinguish social phobic and panic disorder subjects
87. Physical disability and social phobia
88. Social phobia and clonazepam
89. Do specific anxiety disorders show specific drug problems?
90. Social phobia: Historical and conceptual perspectives
91. Magnetic resonance imaging in social phobia
92. Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia
93. Comorbidity of panic and major depressive disorder
94. A pilot study of treatment of social phobia with alprazolam
95. Clonazepam for the treatment of social phobia
96. The etiology of social phobia
97. Prevalence of personality disorders among patients with anxiety disorders
98. Age at onset, precipitating events, sex distribution and co-occurrence of anxiety disorders
99. Fluoxetine in social phobia
100. Placebo-controlled trial of moclobemide in social phobia
101. Social phobia: Comorbidity and morbidity in an epidemiology sample
102. Buspirone in social phobia
103. Comparison of bulimics, obese binge eaters, social phobics and individuals with panic disorder on comorbidity across DSM-IIIR anxiety disorders
104. Comparison of cognitive therapy versus pharmacotherapy in social phobia
105. The validity of the Mini International Neuropsychiatric Interview (M.I.N.I.) according to the SCID-P and its reliability
106. The Mini International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
107. Imipramine in the treatment of social phobia
108. Low dose selegiline (L-deprenyl) in social phobia
109. A twin study of DSM-IIIR anxiety disorders
110. Neurobiological perspectives on social phobia: From affiliation to zoology
111. Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind, placebo-controlled discontinuation
112. G-protein level quantification in platelets and leukocytes from patients with panic disorder
113. Sleep impairment in patients with social phobia
114. A brain single photon emission computed tomography (SPECT) study of generalized social phobia
115. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
116. Social phobic symptoms in patients with panic disorder: Practical and theoretical implications
117. Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders: Comparison of patients with panic disorder and social phobia and normal control subjects
118. Setting diagnostic thresholds for social phobia: Considerations from a community survey of social anxiety
119. Fluoxetine treatment of social phobia
120. Clinical phobias and avoidant personality disorder among alcoholics admitted to an alcoholism rehabilitation setting
121. Neuroendocrine responsivity to monaminergic system probes in generalized social phobia
122. Meta-analysis of cognitive-behavioral treatments for social phobia
123. Dopamine reuptake site densities in patients with social phobia
124. Genetic factors in anxiety disorders
125. Social phobia: Axis I and II correlates
126. Psychopathology of social phobia and comparison to avoidant personality disorder
127. Social phobia: A comparison of behavior therapy and atenolol
128. Social phobia: A comparison of behavior therapy and atenolol
129. Social phobia: A comparison of specific and generalized subtypes and avoidant personality disorder
130. Relationship of social phobia with other psychiatric illness
131. Fluoxetine efficacy in social phobia
132. Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
133. Psychopharmacological treatment of social phobia: A double-blind placebo-controlled study with fluvoxamine
134. Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study
135. Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls
136. Tranylcypromine in social phobia
137. Fobia social
138. Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine
139. Identification of cases of anxiety disorders and affective disorders in the community according to ICD-10 and DSM-IIIR, by using the Composite International Diagnostic Interview (CIDI)
140. Social phobia in general health care: An unrecognized undertreated disabling disorder
141. Christchurch's psychiatric epidemiological study: Methodological and lifetime prevalence for specific psychiatric disorders
142. Exposure in vivo vs. social skills training for social phobia: Long-term outcome and differential effects
143. Treatment of phobias: A comparison of imipramine and placebo